Skip to main content

Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes

Objective

In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any contaminant has to be discarded with the most drastic measures. Such « negative » approach comes at the expense of the recovery of product : yields are poor, thereby inducing a high product cost. Processes are also complex, since they rely on multiple eliminations rather than on recovery of the unique product of interest. Technically, this is mostly due to the lack of specific capture systems that would allow direct, « positive » separation of the vaccine from its environment.Vaccines know no borders. For developing countries, the pressure on costs is even more acute, and local production is a way to try to reach the 1$ per dose target. In this context, water sustainability is a major issue, as it is a most sensitive ingredient in bioproduction.
DiViNe will tackle theses cost and environmental issues with technological answers. The partners will combine two major Nano/biotechnology innovations to develop an integrated purification platform amenable to the different natures of vaccines : glycoconjugates, protein antigens and enveloped viruses. They will implement Nanofitins (novel affinity capture ligands) and Aquaporin-based membranes (energy-saving nano-biomimetics used in the cleantech industry), for a « positive » purification approach. High yields are expected (data from antibody purification with Nanofitins), at affordable cost of goods and with a sustainable approach of water recycling.
Novartis Vaccines brings to the Consortium a broad range of targets, and identical strategies can be applied for biopharmaceuticals in general. The development custom affinity capture processes as a sustainable platform is therefore economically relevant, in a very large market. Beyond the technical partnership, the project is a first run for the partners to structure the platform as a commercial offer for downstream processing of biologics.

Field of science

  • /natural sciences/biological sciences/microbiology/virology
  • /medical and health sciences/health sciences/infectious disease/RNA virus
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins
  • /engineering and technology/environmental engineering/waste management/waste treatment processes/recycling
  • /engineering and technology/environmental engineering/water treatment processes/wastewater treatment processes

Call for proposal

H2020-LEIT-BIO-2014-1
See other projects for this call

Funding Scheme

IA - Innovation action

Coordinator

INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA
Address
Avenida Da Republica Quinta Do Marques
2781-901 Oeiras
Portugal
Activity type
Research Organisations
EU contribution
€ 1 663 706,25

Participants (5)

AFFILOGIC
France
EU contribution
€ 1 146 225
Address
Bio Ouest 21 Rue La Noue Bras De Fer
44200 Nantes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
AQUAPORIN AS
Denmark
EU contribution
€ 519 400
Address
Nymollevej 78
2800 Kobenhavn
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN
Germany
EU contribution
€ 1 397 000
Address
Frankfurter Strasse 250
64293 Darmstadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GENIBET - BIOPHARMACEUTICALS SA
Portugal
EU contribution
€ 250 250
Address
Avenida Da Republica Quinta Do
2781 901 Oeiras
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GLAXOSMITHKLINE VACCINES SRL
Italy
EU contribution
€ 813 999,25
Address
Via Fiorentina 1
53100 Siena
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)